Do Oil Glands Come Back After Accutane? What Studies Show
Share
Short answer: yes, for most people oil glands recover at least partly after Accutane (isotretinoin). The drug shrinks sebaceous glands and cuts oil output sharply during treatment, but it doesn't permanently remove them. Studies that tracked oil levels after treatment found a wide range: some people were back to their old levels within about 7 months, while others still made 30% to 80% less oil more than a year later. There's no reliable study that gives a "percent of oil glands" that come back, because researchers measure gland size and oil output, not gland counts.
What does Accutane do to your oil glands?
Isotretinoin works largely by suppressing the sebaceous (oil) glands. Two things happen:
- The glands shrink. In skin samples taken during treatment, sebaceous glands shrank by up to 90% of their pretreatment size after 12 weeks (Landthaler et al., 1980).
- Oil output drops fast. In early trials, oil production fell by about 75% within 4 weeks (Jones et al., 1980). At a dose of 1 mg/kg a day, it fell to roughly 10% of the starting level (Farrell et al., 1980).
Acne bacteria drop too. One study found bacteria counts fell after oil output did, which suggests the oil drop comes first (King et al., 1982).
Do oil glands grow back after Accutane?
Mostly, yes, but on very different timelines. Here's what the studies that measured oil after treatment actually found:
| Study | Who | What happened after stopping |
|---|---|---|
| Leyden and McGinley, 1982 | 10 people with severe nodulocystic acne | Oil levels trended back toward pretreatment levels within 2 months |
| Strauss and Stranieri, 1982 | 20 people, off the drug at least 20 weeks | 7 were back to pretreatment oil levels by 30 weeks; 8 still had 30% to 80% less oil gland activity for as long as 80 weeks |
| Stewart et al., 1983 | 20 people on three dose levels | Oil output "recovered slowly" after the drug was stopped |
| Hughes and Cunliffe, 1994 | 30 people after a 4-month course | Oil output was 83% lower at the end of treatment and still 36% lower at 1 year |
Put together: the glands are suppressed, not destroyed. Some people bounce back within months; others keep a meaningful reduction for a year or longer. These are small, older studies, so they can't predict where you'll land.
There's one more detail worth knowing. In the Hughes and Cunliffe study, people whose acne came back at 1 year had more oil stored in their pores (the "follicular reservoir") than those who stayed clear. So how much oil returns may be part of why acne returns for some people.
What percent of oil glands come back after Accutane?
The honest answer: no study we found has measured it. Researchers don't count glands before and after treatment. They measure how big the glands are (in skin biopsies) and how much oil reaches the surface.
The framing also misses how glands work. The number of sebaceous glands stays roughly the same throughout life, while their size changes (Zouboulis, 2004). So the better question is how much oil they make again, and the data above suggests anything from a full return to a lasting partial reduction.
How long until oily skin comes back after Accutane?
For some people, oiliness starts returning within a couple of months; others stay drier for more than a year. Oily skin a few months after your course fits what researchers have seen and doesn't on its own mean acne is coming back.
Why does acne come back after Accutane?
Most people do well long term, but relapse is common enough to plan for. Rates depend on how relapse is defined and how long people are followed:
- 22.5% had acne relapse in a US claims study of 19,907 people followed at least a year after isotretinoin, and 8.2% took a second course (Lai and Barbieri, 2025).
- 25.9% had a recurrence over a median of 20 months in a study of 351 people with severe acne (Song et al., 2026).
- 32.7% relapsed by 12 months in a US study of 116 people, but only 1.72% needed a second course (Blasiak et al., 2013).
- 37.3% relapsed in a study of 212 people, with a median time to relapse of 10 months (Demirci Saadet, 2021).
Factors linked to relapse
Cumulative dose. In the large claims study, a higher total dose (mg per kg of body weight over the whole course) was linked to less relapse, while the daily dose didn't matter much once the total was conventional or high (Lai and Barbieri, 2025). In one study, relapse was 47.4% under 220 mg/kg versus 26.9% at or above it (Blasiak et al., 2013). But a 2026 randomized trial found no benefit to going from 120 to 150 mg/kg: relapse was 26.7% versus 32.3% at 12 months, a difference that wasn't significant (Cascio Ingurgio et al., 2026). Your prescriber decides the right course for you.
Age. Several studies link younger age to relapse, including being 20 or younger (Demirci Saadet, 2021) and starting acne early (Quéreux et al., 2006).
Acne at the end of treatment. Lesions still present when treatment stops, heavy oiliness, acne on the trunk and a family history of acne were all linked to relapse (Quéreux et al., 2006; Demirci Saadet, 2021).
Sex and hormones. Female sex was linked to a 43% higher rate of relapse in the claims study (Lai and Barbieri, 2025). In a study of 96 women with nodulocystic acne, isotretinoin worked equally well with or without polycystic ovary syndrome (PCOS), but PCOS was linked to relapse in the second year after treatment (Cakir et al., 2013). And in the 351-person study, higher free androgen index, higher DHEA-S and lower SHBG at baseline were each independently linked to recurrence, along with insulin resistance and blood fat levels (Song et al., 2026). No single marker predicted relapse well on its own; a combined model did better.
The Accutane first month breakout: how common is it?
A flare at the start of treatment is common, and usually mild. In a study of 244 people starting isotretinoin, 79 (about 32%) had a flare on the face, trunk or both. It was mild in 18%, moderate in 10% and severe in 4.5% (Demircay et al., 2008). Severe flares were more likely in men and in people with severe acne, many comedones (blackheads and whiteheads) or nodules.
How long it lasts isn't well measured. The studies we found describe flares at the beginning of treatment but don't give a reliable average duration. Your prescriber has options if a flare is significant, such as adjusting the dose (Chivot, 2001).
Rarely, a flare becomes acne fulminans, a severe form with painful, crusted lesions and sometimes joint pain or feeling unwell. In a European study of 49 people with acne fulminans, 28 developed it after starting isotretinoin, a median of 45 days in (Dessinioti et al., 2024). If your skin suddenly gets much worse or you feel unwell, contact your prescriber right away. Don't stop or change your dose on your own.
When to test for internal drivers if acne comes back
Isotretinoin is strongly recommended for acne that is severe, scarring, causing distress, or not responding to other treatment (Reynolds et al., 2024). A relapse doesn't mean it failed you. But if acne returns, it can help to look at what may be pushing it from the inside. Consider asking about testing if:
- Your acne came back within a year or two of finishing a course.
- You have irregular periods or extra facial or body hair, which can be signs of excess androgens (Lanzo et al., 2015).
- You've been told you may have PCOS, or it runs in your family.
- You're considering a second course and want more context first.
The markers linked to relapse in the research include SHBG, free androgen levels and DHEA-S (Song et al., 2026). Our guide to low SHBG and acne explains why SHBG matters. If your acne has already returned, our post on why acne comes back after Accutane covers the next steps in more detail.
How BreakoutLabs fits in
The BreakoutLabs Acne Root Cause Test measures 19 biomarkers, including SHBG and DHEA-S, which research has linked to relapse after isotretinoin, plus Free and Total Testosterone. It also covers Albumin, Cortisol, hsCRP, Vitamin D, Vitamin B12, Ferritin, Creatinine and HbA1c. It does not measure insulin, glucose, estrogen, progesterone, thyroid hormones, or the liver and lipid tests used to monitor isotretinoin.
You collect a small blood sample at home with a painless device on the back of your upper arm, in the morning after an 8 to 10 hour fast, Monday to Thursday, and on days 3 to 7 of your cycle if you menstruate. A CLIA-certified lab processes it, and results arrive 5 business days after the lab receives your sample, with a personalized Clear Skin Blueprint you can share with your doctor. The test is for ages 14 and up (14 to 17 with a parent or guardian).
BreakoutLabs also offers access to prescription treatment, including isotretinoin when a physician decides it's right for you. The test itself doesn't treat acne; it gives you and your physician data. See how a test-first approach compares with telehealth treatment.
Frequently asked questions
Is Accutane permanent?
The clearing often lasts, but the effect on oil glands isn't permanent for everyone. Studies show oil output returns fully in some people within months and stays partly reduced in others for more than a year.
Does oily skin come back after Accutane?
For many people, yes, at least partly. Oily skin returning doesn't automatically mean acne will return, though more oil stored in the pores after treatment was linked to relapse in one study.
Can you take Accutane twice?
Yes, some people do. In a US study of nearly 20,000 people, 8.2% took a second course. Whether a second course is right for you is a decision for you and your prescriber.
Why am I breaking out in my first month on Accutane?
An early flare is common: about a third of people in one study had one, and most were mild. Tell your prescriber, especially if it's severe or painful, rather than stopping on your own.
Sources
- Landthaler M, Kummermehr J, Wagner A, Plewig G. Inhibitory effects of 13-cis-retinoic acid on human sebaceous glands. Archives of Dermatological Research. 1980.
- Jones H, Blanc D, Cunliffe WJ. 13-cis retinoic acid and acne. The Lancet. 1980.
- Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid: evaluation of sebum production and the clinical response in a multiple-dose trial. Journal of the American Academy of Dermatology. 1980.
- King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. British Journal of Dermatology. 1982.
- Leyden JJ, McGinley KJ. Effect of 13-cis-retinoic acid on sebum production and Propionibacterium acnes in severe nodulocystic acne. Archives of Dermatological Research. 1982.
- Strauss JS, Stranieri AM. Changes in long-term sebum production from isotretinoin therapy. Journal of the American Academy of Dermatology. 1982.
- Stewart ME, Benoit AM, Stranieri AM, et al. Effect of oral 13-cis-retinoic acid at three dose levels on sustainable rates of sebum secretion and on acne. Journal of the American Academy of Dermatology. 1983.
- Hughes BR, Cunliffe WJ. A prospective study of the effect of isotretinoin on the follicular reservoir and sustainable sebum excretion rate in patients with acne. Archives of Dermatology. 1994.
- Zouboulis CC. Acne and sebaceous gland function. Clinics in Dermatology. 2004.
- Lai J, Barbieri JS. Acne relapse and isotretinoin retrial in patients with acne. JAMA Dermatology. 2025.
- Song LF, Xiao Y, Zhang H. Association of baseline peripheral sex hormone profiles and metabolic parameters with recurrence after oral isotretinoin treatment in patients with severe acne. Frontiers in Endocrinology. 2026.
- Blasiak RC, Stamey CR, Burkhart CN, Lugo-Somolinos A, Morrell DS. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatology. 2013.
- Demirci Saadet E. Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris. Dermatologic Therapy. 2021.
- Cascio Ingurgio R, Alfano A, Costanzo A, et al. Cumulative isotretinoin dosing, treatment response and acne relapse: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. 2026.
- Quéreux G, Volteau C, N'Guyen JM, Dréno B. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology. 2006.
- Cakir GA, Erdogan FG, Gurler A. Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse. International Journal of Dermatology. 2013.
- Demircay Z, Kus S, Sur H. Predictive factors for acne flare during isotretinoin treatment. European Journal of Dermatology. 2008.
- Chivot M. Acne flare-up and deterioration with oral isotretinoin. Annales de Dermatologie et de Vénéréologie. 2001.
- Dessinioti C, Dréno B, Bettoli V, et al. Isotretinoin-associated acne fulminans: a multicentre, retrospective study of the European Academy of Dermatology and Venereology Task Force on Acne, Rosacea and Hidradenitis Suppurativa. Journal of the European Academy of Dermatology and Venereology. 2024.
- Lanzo E, Monge M, Trent M. Diagnosis and management of polycystic ovary syndrome in adolescent girls. Pediatric Annals. 2015.
- Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. 2024.
This article is for educational purposes and is not medical advice. Talk to your healthcare provider about testing and treatment.